Lenvatinib enhances antitumor immunity by promoting the infiltration of TCF1+ CD8+ T cells in HCC via blocking VEGFR2

Mei, ZB; Gao, XX; Pan, CX; Wu, QCA; Wang, S; Qian, JJ; Xu, ZT; Xu, KD; Zhou, L; Zhen, SS

Zhou, L; Zhen, SS (通讯作者)，Zhejiang Univ, Sch Med, Div Hepatobiliary & Pancreat Surg, Dept Surg,Affiliated Hosp 1, Hangzhou, Zhejiang, Peoples R China.

CANCER SCIENCE, 2023; 114 (4): 1284

Abstract

Lenvatinib is the favorable treatment for advanced hepatocellular carcinoma (HCC), and it is currently undergoing phase III clinical trials. However, ......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索